
Scanning electron micrograph of Mycobacterium tuberculosis bacteria, which cause TB.NIAID
A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system.
The Phase 1 trial was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. A non-temperature stable form of the candidate previously had been tested in several clinical trials. However, this was the first clinical trial of any subunit TB vaccine candidate in a temperature-stable (thermostable) form. Results are published in Nature Communications.
The experimental vaccine, ID93+GLA-SE, was developed by Christopher B. Fox, Ph.D., and scientists at the Access to Advanced Health Institute (formerly the Infectious Disease Research Institute) in Seattle. It is a recombinant subunit vaccine made from four proteins of Mycobacterium tuberculosis bacteria combined with GLA-SE, an immune-stimulating adjuvant. The freeze-dried formulation does not require refrigeration and is mixed with sterile water just prior to injection. Thermostable vaccines are desirable in settings where maintaining cold or frozen vaccines for long periods can be costly and difficult.
The current trial investigated whether administering temperature-stable vaccine containing both ID93 and GLA-SE in a single vial would be as effective at inducing an immune response as a regimen in which non-thermostable ID93 and liquid GLA-SE are held in two vials and combined prior to injection. A single-vial presentation of a thermostable vaccine would have clear advantages in ease of storage, transport and administration, the investigators note.
Daniel F. Hoft, M.D., Ph.D., director of the Saint Louis University Center for Vaccine Development, led the single-site trial at the university’s School of Medicine. Twenty-three participants received the thermostable single-vial regimen, while 22 participants received the two-vial, non-thermostable regimen. Both vaccine presentations were safe and well-tolerated. Recipients of the single-vialled thermostable vaccine had robust T-cell responses and produced higher levels of antibodies in the blood than those receiving the non-thermostable two-vial presentation.
The investigators note some limitations in this small trial. For example, no established correlates of protection define what immune responses are required for vaccine-induced protection from TB disease. Therefore, it is not possible to say whether the enhanced immune responses seen in the thermostable vaccine formulation would translate to improved protective vaccine efficacy. Nevertheless, they conclude, results of this trial demonstrate “a proof-of-concept that adjuvant-containing vaccines can be formulated in a freeze-dried single-vial presentation without detrimentally impacting clinical immunogenicity or safety characteristics.”
Original Article: Temperature-Stable TB Vaccine Safe, Prompts Immune Response in NIH-Supported Study
More from: National Institutes of Health | Saint Louis University
The Latest Updates from Bing News
Go deeper with Bing News on:
Tuberculosis vaccine
- We have the right tools to do more against tuberculosis
Improved screening is important, and the treatment for latent TB has made great strides, a biotech firm director writes.
- WHO Launches Tuberculosis Research Tracker Online Platform
Researchers, national TB programs, donors, and technical agencies will be periodically contacted to ensure the timely update of the platform.
- Bharat Bio seeks nod for TB vaccine trials
India is home to more than 2 million TB patients and the Union health ministry is running several programmes to eliminate TB by 2025.
- Novavax teams with Gates Foundation in efforts to develop malaria, TB shots
Novavax also offered an update on its COVID-19 booster ahead of a meeting by FDA advisers to decide this year’s strain selection.
- The resurgence of ‘ticking timebomb’ tuberculosis
After two decades in decline rates are rising as a result of Covid and global conflicts Tuberculosis is set to overtake Covid-19 as the world’s most deadly infectious disease, with medical experts ...
Go deeper with Bing News on:
TB vaccine
- We have the right tools to do more against tuberculosis
Improved screening is important, and the treatment for latent TB has made great strides, a biotech firm director writes.
- WHO Launches Tuberculosis Research Tracker Online Platform
Researchers, national TB programs, donors, and technical agencies will be periodically contacted to ensure the timely update of the platform.
- Bharat Bio seeks nod for TB vaccine trials
India is home to more than 2 million TB patients and the Union health ministry is running several programmes to eliminate TB by 2025.
- Novavax teams with Gates Foundation in efforts to develop malaria, TB shots
Novavax also offered an update on its COVID-19 booster ahead of a meeting by FDA advisers to decide this year’s strain selection.
- Novavax gets attention from Bill & Melinda Gates researchers
Its Matrix-M adjuvant is the basis for its protein-based COVID-19 vaccine, and is being used in development of new influenza and combination influenza-COVID vaccines.